TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19114912

Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 200
Study: 16924187

Group type: EXPERIMENTAL
Intervention: Proxy report
Number of subjects: 47
Study: 14755377

Group type: EXPERIMENTAL
Intervention: Pre-treatment MM group (serum IL-16 level)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patients with high IL-16 levels (>430 pg/ml)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Post-treatment MM group (after chemotherapy)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Disease stage progression (from stage I to stage III)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pre-treatment MM group (correlation with alpha1AT and IL-6)
Number of subjects: 48
Study: 12774003

Group type: EXPERIMENTAL
Intervention: Propranolol + placebo
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Propranolol + IS‐MN
Number of subjects: 349
Study: 10895566

Group type: EXPERIMENTAL
Intervention: Conceptually driven tests
Number of subjects: 2

Group type: COMPARATOR
Intervention: Perceptually driven tests
Number of subjects: 2
Study: 9151629

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine spray, twice daily for 30 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine spray, twice daily for 30 days
Number of subjects: 8
Study: 1407193

Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant administration (n = 42)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Therapeutic surfactant administration (n = 39)
Number of subjects: 81
Study: 4004197

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (once-daily intramuscular injection) for a mean of 4.0 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cefazolin (every 8 hours) for a mean of 4.5 days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (once-daily intramuscular injection)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cefazolin (every 8 hours)
Number of subjects: 57
Study: 3147588

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30281507

Group type: EXPERIMENTAL
Intervention: Randomized radial basis function network model for educational level classification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other well-referenced machine learning models
Number of subjects: 0
Study: 30929618

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention program (CBP)
Number of subjects: 316
Study: 26546305

Group type: EXPERIMENTAL
Intervention: Cancer Risk Check (CRC)
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Text-based control (online PDF file)
Number of subjects: 1452
Study: 26000668

Group type: EXPERIMENTAL
Intervention: 125 mg transmucous-buccal acetaminophen (B-APAP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1 g intravenous acetaminophen (iv-APAP)
Number of subjects: 40
Study: 23097053

Group type: EXPERIMENTAL
Intervention: Violent video game
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 77
Study: 21709061

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg thrice per day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 19843490

Group type: EXPERIMENTAL
Intervention: MgV solution 500 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MgV suspension 500 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MgV enteric-coated tablets 500 mg
Number of subjects: 24
Study: 16915900

Group type: EXPERIMENTAL
Intervention: Induction dose of ketamine (6 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low dose of ketamine (3 mg/kg)
Number of subjects: 40
Study: 15044506

Group type: EXPERIMENTAL
Intervention: Electronic nose in 'top-note' mode
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Log VSC measurements
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Top-note score
Number of subjects: 78
Study: 11581108

Group type: COMPARATOR
Intervention: Standard dose depot antipsychotic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depot antipsychotics
Number of subjects: 0
Study: 9645717

Group type: EXPERIMENTAL
Intervention: 0.05% olopatadine
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 0.1% olopatadine
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 8164297

Group type: EXPERIMENTAL
Intervention: 10 g of wheat bran (WB)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 30 g of wheat bran (WB)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 10 g of vegetable fiber (VF)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 30 g of vegetable fiber (VF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0 g of fiber (control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: wheat bran (WB)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: vegetable fiber (VF)
Number of subjects: 34
Study: 3344909

Group type: EXPERIMENTAL
Intervention: Extended highly selective vagotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Highly selective vagotomy
Number of subjects: 0
Study: 31498885

Group type: EXPERIMENTAL
Intervention: In-house developed TPS (Solo)
Number of subjects: 10
Study: 28528342

Group type: EXPERIMENTAL
Intervention: Nutricosmeceutical containing collagen bioactive peptides and antioxidants (50 mL daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (50 mL daily)
Number of subjects: 120
Study: 25398726

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 47
Study: 23220477

Group type: EXPERIMENTAL
Intervention: Acetaminophen (4.0 g/day; n = 11)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1.2 g/day; n = 13)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 36
Study: 25090744

Group type: COMPARATOR
Intervention: Oral midazolam 0.6 mg/kg alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.6 mg/kg with nitrous oxide-oxygen inhalation
Number of subjects: 30
Study: 18996631

Group type: EXPERIMENTAL
Intervention: Ultrasonic retrotip
Number of subjects: 47

Group type: COMPARATOR
Intervention: Microhead bur
Number of subjects: 47
Study: 16974193

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 26
Study: 15074998

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study: 11289484

Group type: EXPERIMENTAL
Intervention: Microalbuminuria cases (MA)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Normoalbuminuric control subjects
Number of subjects: 494
Study: 9398709

Group type: EXPERIMENTAL
Intervention: Combination therapy with insulin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Insulin therapy alone
Number of subjects: 100
Study: 7956640

Group type: EXPERIMENTAL
Intervention: Gastroparetic patients
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 11
Study: 2890951

Group type: EXPERIMENTAL
Intervention: Dipyridamole 75 mg plus acetylsalicylic acid 325 mg (DP‐ASA)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 29295035

Group type: EXPERIMENTAL
Intervention: Domestic violence (any type)
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Controlling behavior
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Emotional violence
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Sexual violence
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Physical violence
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Younger age (30 to 40 years)
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Age (41 to 50 years)
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Lack of emotional support
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Lack of tangible support
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Perceived poor self-health
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Husbands' poor health
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Polygamy
Number of subjects: 1883
Study: 30882475

Group type: EXPERIMENTAL
Intervention: Airway closure group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 50
Study: 27142099

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoroscopy imaging
Number of subjects: 50
Study: 24957485

Group type: COMPARATOR
Intervention: safflower oil (HL) 51.7 kcal
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: high-dose casein (HP) 51.7 kcal
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: high-dose sucrose (HC) 51.7 kcal
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: low-dose casein (LP) 17.2 kcal
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: low-dose sucrose (LC) 17.2 kcal
Number of subjects: 13

Group type: COMPARATOR
Intervention: control (C) saline
Number of subjects: 13
Study: 24112417

Group type: EXPERIMENTAL
Intervention: 14-week intensive intervention including breastfeeding benefits, understanding GDM, nutrition and exercise education, coping skills training, physical activity, educational and motivational text messaging, and 3 months of continued monthly contact
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 14-week intensive intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 100
Study: 21509429

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA for 20 minutes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA for 20 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS (20 minutes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 20
Study: 19632943

Group type: EXPERIMENTAL
Intervention: Pemetrexed/carboplatin/bevacizumab induction followed by pemetrexed/bevacizumab maintenance
Number of subjects: 900

Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin/bevacizumab induction followed by bevacizumab maintenance
Number of subjects: 900
Study: 17980497

Group type: EXPERIMENTAL
Intervention: Gonadotropin Releasing Hormone analogue (GnRHa) treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (wait-listed volunteers)
Number of subjects: 15
Study: 15073842

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan/5‐FU/LV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin/5‐FU/LV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan and oxaliplatin in combination with infusional 5‐FU/LV
Number of subjects: 0
Study: 11842947

Group type: EXPERIMENTAL
Intervention: NaHCO3 2 mmol/kg/d for 7 days
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: NaCl 2 mmol/kg/d for 7 days
Number of subjects: 149

Group type: COMPARATOR
Intervention: No special therapy
Number of subjects: 149

Group type: COMPARATOR
Intervention: Modification of mineral content of standard preterm formula
Number of subjects: 149
Study: 9379066

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 90 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 10
Study: 8094308

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor (GM-CSF) at a starting dose of 250 micrograms/m2/day as continuous infusion via the IVC catheter.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Aspirin (325 mg daily) given to both groups.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mechanical clot aspiration used for occlusions during GM-CSF therapy.
Number of subjects: 66
Study: 3666667

Group type: EXPERIMENTAL
Intervention: Pirenzepine 2 X 25 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Pirenzepine 2 X 50 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study: 30139501

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Medical rate control
Number of subjects: 36
Study: 26808077

Group type: EXPERIMENTAL
Intervention: Lumbar drain (LD) placement in Group A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conservative management (bed rest and head elevation) in Group B
Number of subjects: 60
Study: 24400920

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 30
Study: 24250451

Group type: EXPERIMENTAL
Intervention: Propofol-midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol-fentanyl
Number of subjects: 40
Study: 20228638

Group type: EXPERIMENTAL
Intervention: Prevention care manager‐tailored telephone support intervention
Number of subjects: 38
Study: 18398809

Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LSM + MET
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 15971252

Group type: EXPERIMENTAL
Intervention: 6-week prevention program conducted by trained teachers
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 141
Study: 11991780

Group type: EXPERIMENTAL
Intervention: Right-arm trained group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Left-arm trained group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Internal rotation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: External rotation
Number of subjects: 34
Study: 10609068

Group type: COMPARATOR
Intervention: Single DMARD (methotrexate 7.5‐15 mg/week or sulfasalazine 1‐2 g/day or hydroxychloroquine 200 mg/day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Combination of MTX + SSZ or MTX + HCQ
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of MTX + SSZ + HCQ
Number of subjects: 180
Study: 7492036

Group type: EXPERIMENTAL
Intervention: 60 mg of IM ketorolac and oral placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50 mg of oral indomethacin and IM placebo
Number of subjects: 20
Study: 1600964

Group type: EXPERIMENTAL
Intervention: Milrinone 0.375 micrograms kg‐1 min‐1
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Milrinone 0.5 micrograms kg‐1 min‐1
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Milrinone 0.75 micrograms kg‐1 min‐1
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Milrinone (all dosages)
Number of subjects: 99
Study: 6374497

Group type: EXPERIMENTAL
Intervention: Levodopa (supplemental dopamine in precursor form)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 30204516

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg‐1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Torque factor (Toptimal)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sprint duration (10 s)
Number of subjects: 13
Study: 30143033

Group type: EXPERIMENTAL
Intervention: Standard of care plus pharmacist-managed diabetes clinic (SOC + PMDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study: 24619484

Group type: EXPERIMENTAL
Intervention: Difficulties in Emotion Regulation Scale (DERS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DERS goals subscale
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DERS subscales
Number of subjects: 80
Study: 22289212

Group type: EXPERIMENTAL
Intervention: Tailored intervention programme aimed at improving (vigorous) physical activity levels and healthy dietary behaviour, including tailored information, face‐to‐face and telephone counselling, training instruction, and various health-promoting materials.
Number of subjects: 0
Study: 19157609

Group type: EXPERIMENTAL
Intervention: RA2 (double modulated arcs with RapidArc technique)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: RA1 (single modulated arcs with RapidArc technique)
Number of subjects: 29

Group type: COMPARATOR
Intervention: IMRT (conventional fixed field IMRT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: RA1
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: RA2
Number of subjects: 29

Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 29
Study: 17674028

Group type: COMPARATOR
Intervention: Pulsed electromagnetic fields (PEMF) at 0.005 T/s
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pulsed electromagnetic fields (PEMF) at 0.03 T/s
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pulsed electromagnetic fields (PEMF) at 0.09 T/s
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pulsed electromagnetic fields (PEMF) at varying intensities
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (zero intensity)
Number of subjects: 32
Study: 15611975

Group type: EXPERIMENTAL
Intervention: Paclitaxel 70 mg/m² on Days 1 and 8, carboplatin AUC 5 on Day 1, gemcitabine 1000 mg/m² on Days 1 and 8 every 21 days for a maximum of 8 cycles
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and gemcitabine
Number of subjects: 32
Study: 11896773

Group type: EXPERIMENTAL
Intervention: 1064 nm Nd:YAG laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: 810 nm diode laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: 755 nm alexandrite laser
Number of subjects: 30
Study: 9681077

Group type: EXPERIMENTAL
Intervention: CAPOMEt (weekly regimen incorporating cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, and etoposide)
Number of subjects: 381

Group type: COMPARATOR
Intervention: CHOP‐Mtx (cyclical regimen of cyclophosphamide, doxorubicin, vincristine, prednisone, and methotrexate)
Number of subjects: 381

Group type: COMPARATOR
Intervention: CHOP‐Mtx
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: CAPOMEt
Number of subjects: 381
Study: 7999849

Group type: EXPERIMENTAL
Intervention: Treatment with rifampin and bacitracin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 2967829

Group type: EXPERIMENTAL
Intervention: Ioxaglate meglumine/sodium
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 126

Group type: COMPARATOR
Intervention: Diatrizoate meglumine/sodium
Number of subjects: 126
Study: 30301241

Group type: COMPARATOR
Intervention: Control drink (450 mL; 2 kcal)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M280 (14 g protein, 28 g carbohydrate, 12.4 g fat; 280 kcal)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M504 (70 g protein, 28 g carbohydrate, 12.4 g fat; 504 kcal)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: P280 (70 g protein, 0 g carbohydrate, 0 g fat; 280 kcal)
Number of subjects: 13
Study: 28177172

Group type: EXPERIMENTAL
Intervention: VIBRANT capsule treatment for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham capsule treatment for 8 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: VIBRANT capsule treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham capsule treatment
Number of subjects: 24
Study: 26299292

Group type: EXPERIMENTAL
Intervention: Bounce Back Now (BBN)
Number of subjects: 2000
Study: 23987000

Group type: EXPERIMENTAL
Intervention: 1,3-beta-D glucanase detection in plasma
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (patients who underwent endoscopic surgery excluding fungal rhinosinusitis)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison between case and control groups
Number of subjects: 37
Study: 21389338

Group type: EXPERIMENTAL
Intervention: Cognitive-bias modification (CBM) intervention with avoidance movements (pushing a joystick) in response to alcohol pictures
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Cognitive-bias modification (CBM) intervention
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control conditions (no training or sham training)
Number of subjects: 214
Study: 19031710

Group type: EXPERIMENTAL
Intervention: Colon purification treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Routine anti‐coma hepaticum treatments
Number of subjects: 117
Study: 16362397

Group type: EXPERIMENTAL
Intervention: Single-dose intravenous metronidazole 500 mg preoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Broad-spectrum multi-drug regimen (cefuroxime 1.5 g i.v. and metronidazole 0.5 g i.v. preoperatively, co-amoxiclav 375 mg orally 8-hourly postoperatively for 5 days)
Number of subjects: 50
Study: 12921453

Group type: EXPERIMENTAL
Intervention: Cephalexin twice daily
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Cephalexin three times daily
Number of subjects: 271

Group type: COMPARATOR
Intervention: Cefadroxil once daily
Number of subjects: 271
Study: 11029359

Group type: COMPARATOR
Intervention: Bleomycin instillation (60E) via a small-bore thoracostomy tube
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Thoracoscopic talc poudrage (5 g) under local anesthesia
Number of subjects: 36
Study: 8970874

Group type: EXPERIMENTAL
Intervention: Gadolinium-DTPA-BMA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gadolinium-HP-DO3A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gadolinium-DTPA
Number of subjects: 0
Study: 1303855

Group type: EXPERIMENTAL
Intervention: Alfentanil/promazine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meperidine/promazine
Number of subjects: 40
Study: 2580156

Group type: EXPERIMENTAL
Intervention: RO 13‐6438 10 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RO 13‐6438 20 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RO 13‐6438 20 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RO 13‐6438 40 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RO 13‐6438 60 mg orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31839089

Group type: EXPERIMENTAL
Intervention: Group A: periarticular injection of compound analgesics of ropivacaine, ketorolac, adrenaline, morphine and normal saline
Number of subjects: 134

Group type: COMPARATOR
Intervention: Group B: periarticular injection of compound analgesics of bupivacaine, methylprednisolone, adrenaline, morphine and normal saline
Number of subjects: 134